Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 18, 2009

AbD Serotec and BBInternational Ink Reciprocal Marketing Agreement

  • AbD Serotec , the research and diagnostics antibody division of MorphoSys , and BBInternational  signed an agreement to comarket each other’s products and services worldwide.

    The agreement will give BBI’s customers access to over 13,000 antibodies and immunological reagents and custom monoclonal antibodies developed from the MorphoSys HuCAL library, along with AbD Serotec’s large- and small-scale antibody production and conjugation services.

    AbD Serotec will in turn have direct access to BBI’s complementary range of services for the production of gold-labeled reagents, contract research and development, and manufacture of rapid diagnostic tests for point of care markets.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »